• (Z)-4-Hydroxytamoxifen in Relapse Research

  2026-10-13

  (Z)-4-Hydroxytamoxifen is described by APExBIO as an active tamoxifen metabolite and selective estrogen receptor modulator. The supplied 2025 study addresses a different but related question: how tumors recur after preferential loss of proliferating cells in a PyMT mouse model. Its findings support a role for low-cycling tumor reservoirs and remodeled immune and stromal ecosystems, but they do not establish that the study used (Z)-4-hydroxytamoxifen or that its results apply directly to estrogen-dependent breast cancer or patients.

• Angiotensin 1/2 (1-6): Evidence and Boundaries

  2026-10-12

  Angiotensin 1/2 (1-6), identified by the supplier as the Asp-Arg-Val-Tyr-Ile-His hexapeptide, has relevance to renin–angiotensin system research. A 2025 biochemical study reported that this and related angiotensin peptides increased SARS-CoV-2 spike-protein binding to selected host receptors, but the findings do not establish effects on viral infection, disease severity, cardiovascular physiology, or renal function in living systems.

• What the GRE Study Shows About Melanogenesis

  2026-10-12

  A 2025 cell-based study examined glabridin, resveratrol, and ellagic acid as a combined GRE composition. It reported reduced melanin-related readouts, tyrosinase activity, oxidative-stress indicators, nitric oxide production, and CREB/MITF-associated signaling, but the findings remain preclinical and do not establish clinical efficacy for hyperpigmentation disorders.

• 25-Hydroxycholesterol Reprograms TAM AMPK Signaling

  2026-10-11

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal cholesterol sensing to AMPKα, STAT6, and ARG1 in tumor-associated macrophages. The study connects this pathway with immune suppression and reports that CH25H targeting improves T-cell activity and anti-PD-1 responses in tumor models, while leaving clinical applicability to be established.

• Olaparib and BRCA2-Dependent DNA Repair

  2026-10-10

  A source-grounded overview of Olaparib research, focusing on PARP inhibition, BRCA2-dependent nascent-strand maturation, replication-associated DNA damage, conceptual cancer applications, and the limits of translating cell-based findings into clinical or radiosensitization claims.

• GSK621 and AMPK: From Metabolism to Tumor Immunity

  2026-10-09

  GSK621 is an AMPK agonist that offers a useful pharmacological lens on energy sensing, AML biology, and immunometabolic signaling. This article distinguishes direct compound effects from the lysosomal 25-hydroxycholesterol mechanism reported in Immunity, defining what the evidence supports—and what remains unproven.

• Clathrin-Mediated Entry of Grass Carp Reovirus

  2026-10-09

  Wang et al. used complementary inhibitor, microscopy, and quantitative PCR evidence to examine how genotype III grass carp reovirus enters cultured grass carp kidney cells. Their findings support a dynamin-dependent, acidification-dependent clathrin-mediated entry route, while the reported lack of inhibition by Latrunculin B helps distinguish this process from a simple requirement for actin filament assembly.

• Blue Light, EGFR/ERK/c-Jun, and Skin Barrier Damage

  2026-10-08

  A 2026 Journal of Investigative Dermatology study connects repeated blue-light exposure with persistent skin-barrier impairment, epidermal thickening, pigmentation, and increased transepidermal water loss. By combining human observations, mouse models, imaging, histology, and pathway analysis, the work positions EGFR/ERK/c-Jun signaling as a mechanistic framework while highlighting important limits in exposure specificity and causal interpretation.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-10-08

  Oliveira and colleagues reported that several naturally occurring angiotensin peptides increase the measured binding of SARS-CoV-2 spike protein to host-cell receptors, with the strongest effects associated with selected shorter or N-terminally modified fragments. The study introduces a biochemical link between renin-angiotensin system research and viral receptor biology, while its binding-only design means that effects on infection, disease severity, or treatment remain unproven.

• DAMGO and the Circuit Logic of Opioid Pain

  2026-10-07

  DAMGO is more than a selective µ-opioid receptor agonist: it is a mechanistic probe for separating receptor activation from the distributed circuit processes that shape analgesia, mechanical hypersensitivity, and tolerance. New mouse findings connect MOR-expressing brainstem neurons with hypothalamic dynorphin signaling and spinal KOR-GABA circuitry, creating a stronger framework for opioid receptor signaling research and translational pain science.

• FAISL–FAK Control in Triple-Negative Breast Cancer

  2026-10-07

  The 2024 Advanced Science study identifies FAISL as a focal adhesion kinase-interacting lncRNA that stabilizes FAK by limiting Calpain 2-mediated proteolysis. Its combination of transcriptomic discovery, molecular validation, cancer-cell phenotyping, and targeted siRNA delivery links post-translational FAK control to TNBC progression and metastasis, while leaving important questions about clinical transferability and calcium-dependent regulation open.

• GRE Combination and CREB/MITF Control of Melanogenesis

  2026-10-06

  Huang and colleagues evaluated glabridin, resveratrol, and ellagic acid as a combined GRE composition across melanogenesis, antioxidant, and inflammation-related cellular readouts. The study’s main contribution is a mechanism-oriented link between reduced melanin and tyrosinase activity and suppression of CREB phosphorylation and MITF-associated expression, while its in vitro design limits direct conclusions about clinical efficacy or formal ingredient synergy.

• Silk Fibroin–Ce6 Films for Infected Wound Healing

  2026-10-06

  The reference study combines aligned silk fibroin electrospun fibers with covalently associated Chlorin e6 to create an anisotropic wound film that couples cell-guidance properties with photodynamic antibacterial activity. Its reported findings support a preclinical strategy for controlling Staphylococcus aureus infection while influencing later-stage macrophage behavior, but they do not establish clinical efficacy or anticancer activity.

• Ciprofloxacin in Nanotheranostic Research

  2026-10-05

  This overview examines Ciprofloxacin as a fluoroquinolone antibiotic and research compound, with emphasis on its established bacterial DNA-targeting mechanism and a 2026 preclinical nanotheranostic study in triple-negative breast cancer. It separates reported findings from interpretation and outlines evidence limitations, translational boundaries, and implications for antimicrobial resistance research.

• Mouse Tissue Lysis Kit K1038: Product Overview

  2026-10-05

  The Mouse Tissue Lysis Kit (K1038) is an APExBIO research product described for tissue lysis and direct genotyping workflows. No matched peer-reviewed paper evidence was provided, so performance, reproducibility, and applicability cannot be independently assessed.

7791 records 1/520 page Next 12345 下5页 Last page